Summary and Key References

The Drug Safety Lifecycle transforms pharmacovigilance from a regulatory reporting obligation into an intelligent, continuous process that connects preclinical prediction, clinical observation, post-marketing surveillance, and real-world evidence into a unified ecosystem of accountability. Its key characteristics in 2026 are: circularity (each phase informs the others); integration (PV operates across clinical, regulatory, and quality functions simultaneously); adaptivity (AI tools enable real-time data processing and predictive analytics at scale); and human governance (all AI-assisted activities remain under qualified human oversight, per CIOMS WG XIV, the EU AI Act, and FDA-EMA joint principles).

For the PV professional — whether entering the field or leading a safety function — understanding the full lifecycle context of every case processed, every signal reviewed, and every report submitted is what separates compliance from genuine patient protection. The data you handle is part of a story that began in a laboratory and will continue long after the specific case you are reviewing is closed.

Key references: ICH M3(R2) Nonclinical Safety Studies · ICH S-series guidelines (S2(R1), S5(R3), S6(R2), S7A, S7B, S9, S11) · ICH E2A · ICH E2E · ICH E6(R3) · EMA GVP Module V (Risk Management Systems) · EMA GVP Module I Rev 3 (2025) · Commission Implementing Regulation (EU) 2025/1466 · CIOMS Working Group XIV Final Report (December 2025) · EMA PROTECT project (MCDA) · ICH E2C(R2) (PBRER) · ICH E2F (DSUR).